

CUMBERLAND PHARMACEUTICALS INC  
Form 8-K  
February 03, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 3, 2017 (January 30, 2017)

Cumberland Pharmaceuticals Inc.

---

(Exact name of registrant as specified in its charter)

|   |                                |                                      |
|---|--------------------------------|--------------------------------------|
| Tennessee   | 001-33637                      | 62-1765329                           |
| (State or other jurisdiction of incorporation)        | (Commission<br>File<br>Number) | (I.R.S. Employer Identification No.) |
| 2525 West End Avenue, Suite 950, Nashville, Tennessee |                                | 37203                                |
| (Address of principal executive offices)              |                                | (Zip Code)                           |

Registrant's telephone number, including area code: (615) 255-0068  
Not Applicable

---

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

On January 30, 2017, the Company issued a press release announcing the Appeals Court ruling in favor of Cumberland in a patent case associated with its Acetadote product. A copy of the press release is furnished as Exhibit 99.1 as well as the Company's updated risk disclosure related to Acetadote at Exhibit 99.2.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

February 3, 2017 By: Michael Bonner

Name: Michael Bonner

Title: Chief Financial Officer